Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nimodipine Clear all
Withdrawn Phase 4 Interventional

RCVS: The Rational Approach to Diagnosis and Treatment

NCT03150524
View directory record Official record
Conditions
Reversible Cerebral Vasoconstriction Syndrome
Interventions
TCD- cerebral blood flow velocities, Headache pain score, Neurological examination, Repeat Neuroimaging, Nimodipine, Verapamil ER
Diagnostic Test · Behavioral · Other + 1 more
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations

NCT01835665
View directory record Official record
Conditions
Progranulin Mutation Carriers
Interventions
Nimodipine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 3, 2026, 9:32 PM EDT
Terminated Phase 4 Interventional Results available

Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression

NCT00781326
View directory record Official record
Conditions
Depression
Interventions
Nimodipine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 3, 2026, 9:32 PM EDT
Terminated Phase 1 Interventional

Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

NCT02893826
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
EG-1962 (nimodipine microparticles), Enteral Nimodipine
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Phoenix, Arizona • San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

NCT00000738
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Nimodipine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 3, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Nimodipine Variability in SAH

NCT07065903
View directory record Official record
Conditions
Subarachnoid Aneurysm Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Early Phase 1 Interventional

Cognitive Effects of Nimodipine in Patients With Schizophrenia

NCT03671525
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Nimodipine, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

High Dose Nimodipine Treatment Adjunct - 1

NCT00000332
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Nimodipine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
22 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 3, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

NCT05995405
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
GTX-104, Nimotop 30 MG Oral Capsule
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 3, 2026, 9:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders

NCT00001478
View directory record Official record
Conditions
Healthy, Mood Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

NCT01672801
View directory record Official record
Conditions
Unexplained Infertility, Polycystic Ovarian Syndrome, Anovulatory
Interventions
Placebo, Nimodipine
Drug
Lead sponsor
Boston IVF
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 3, 2026, 9:32 PM EDT
Not yet recruiting Phase 2 Interventional

Pilot Study: Effects of Nimodipine on Alcohol Drinking

NCT06900998
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Nimodipine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 3, 2026, 9:32 PM EDT
Terminated No phase listed Observational

SHERLOCK 3CG™ Diamond Tip Confirmation System

NCT03288766
View directory record Official record
Conditions
Indication for Peripheral Intravenous Catheterization, Atrial Flutter, Premature Atrial Contraction, Premature Ventricular Contraction, Premature Junctional Contraction, Tachycardia, Atrioventricular Block, Bundle-Branch Block
Interventions
PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Las Vegas, Nevada • Greensboro, North Carolina • Greenville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 3, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

NCT02790632
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
EG-1962 (nimodipine microparticles), Enteral Nimodipine
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 3, 2026, 9:32 PM EDT
Terminated Phase 4 Interventional

Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT04148105
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Cilostazol 100 MG, Placebo
Drug · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 3, 2026, 9:32 PM EDT
Completed No phase listed Observational

Study to Assess Electrocardiogram Waveforms Produced Through the Utilization of the Sherlock 3CG™ Tip Confirmation System

NCT03028090
View directory record Official record
Conditions
Indication for Peripheral Intravenous Catheterization
Interventions
SHERLOCK 3CG™ Tip Confirmation System with MODUS Software
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Colorado Springs, Colorado • Montgomery, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Glutaminergic Agents for Cocaine Abuse - 5

NCT00000280
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Nimodipine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 3, 2026, 9:32 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Verily Clinical Study Watch Analytical Validation Study

NCT05534477
View directory record Official record
Conditions
Healthy Population, Chronic Disease
Interventions
Verily Clinical Study Watch, Vivalink ECG Patch, Modus StepWatch 4
Device
Lead sponsor
Verily Life Sciences LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 3, 2026, 9:32 PM EDT
Not yet recruiting Phase 2 Interventional

Effects of Nimodipine on Alcohol Drinking

NCT07681869
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Nimodipine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 9:32 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

NCT01893190
View directory record Official record
Conditions
Ruptured Cerebral Aneurysm, Ruptured Berry Aneurysm
Interventions
Nimodipine, Nimodipine Microparticles
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 3, 2026, 9:32 PM EDT